Future studies could assess the therapeutic potential of inhibiting PANK4 phosphatase activity to increase CoA synthesis in patients with pantothenate-kinase-associated neurodegeneration or selectively inhibiting CoA synthesis in PI3K-dependent cancers. This evidence concerns the gene PANK1 and cancer.